Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's IPR (intellectual property rights) enforcement promises followed up by US:

This article was originally published in Clinica

Executive Summary

China's claims that progress is being made to enforce intellectual property rights (IPR) are to be assessed by the World Trade Organisation (WTO) at the behest of the US. What is known as an "Article 63" request has been made by the US Trade Representative (USTR) and requires that China detail the specific actions it has taken to enforce IPR. Article 63.3 is part of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which allows WTO members to request information on judicial decisions or administrative rulings related to IPR that affects their rights under the agreement. The move highlights the continuing US concerns that China has not provided sufficient detail about its IPR enforcement programme. The action builds on the July US-China Joint Commission on Commerce and Trade meeting in Beijing.

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts